{"id":"W2790684790","doi":"10.1111/jdv.14913","title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","year":2018,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Valeant Pharmaceuticals International","keywords":"Medicine; Ustekinumab; Psoriasis; Randomized controlled trial; Placebo; Visual analogue scale; Dermatology Life Quality Index; Ixekizumab; Internal medicine; Dermatology; Physical therapy; Secukinumab; Adalimumab; Psoriatic arthritis; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00694296,0.001506106,0.004416487,0.0008253558,0.0006666309,0.001724623,0.001283024,0.002310414,0.006844196],"category_scores_gemma":[0.006550234,0.000770549,0.004797234,0.001190172,0.0009276443,0.001003398,0.0004853956,0.002467295,0.0005712348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009508219,"about_ca_system_score_gemma":0.001735124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009547926,"about_ca_topic_score_gemma":0.0030657,"domain_scores_codex":[0.9965817,0.002072536,0.0004334691,0.0003405404,0.0003085207,0.0002632211],"domain_scores_gemma":[0.9968927,0.001140312,0.001143084,0.0001812405,0.0002747022,0.0003678833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.908878,0.003701296,0.001376583,0.01682279,0.01358775,0.0001062663,0.0001049495,0.0005546523,0.002723267,0.0002817913,0.003961115,0.04790141],"study_design_scores_gemma":[0.980838,0.01264594,0.001873587,0.000474848,0.002308008,0.00004285723,0.00001623303,0.0001824373,0.0001718394,0.0001418984,0.00128898,0.00001531368],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6438082,0.2790598,0.006377923,0.005385097,0.003666734,0.04285948,0.006838103,0.00108403,0.01092073],"genre_scores_gemma":[0.8596151,0.07546771,0.007181653,0.006682036,0.001341781,0.04315373,0.003247925,0.0001054542,0.003204613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00694296,"threshold_uncertainty_score":0.03671831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02023143258453447,"score_gpt":0.2847596844312664,"score_spread":0.2645282518467319,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}